구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
기전. Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TSLP (thymic stromal lymphopoietin)
Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps
US, EU, JP
Approved
tezspire · tezepelumab · Tezspire · AMG 157 · MEDI9929 · tezepelumab-ekko
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG2 monoclonal antibody
Binds TSLP and prevents interaction with the TSLPR/IL-7Rα receptor complex
Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers.
구조화 데이터
Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers.
Non-inflammatory structural airway disease does not respond to cytokine blockade.
Human IgG2 monoclonal antibody
TSLP (thymic stromal lymphopoietin) · Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility.
Pharyngitis, arthralgia, and injection-site reactions; parasitic infection screening
The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
Severe asthma inadequately controlled on high-dose ICS plus another controller, regardless of phenotype
Add-on maintenance
Subcutaneous, self-administration pen available
210 mg q4w
Pharyngitis, arthralgia, and injection-site reactions; parasitic infection screening
The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation.
Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility.
Non-inflammatory structural airway disease does not respond to cytokine blockade.
구조화 데이터
Human, cynomolgus
~26 days
Annualized exacerbation rate, pre-bronchodilator FEV1, FeNO, blood eosinophils
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (severe asthma add-on)
APPROVAL · 2021년 12월
Self-administration pen approved
APPROVAL · 2023년 2월
Chronic rhinosinusitis with nasal polyps indication
APPROVAL
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
기전. Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TSLP (thymic stromal lymphopoietin)
Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps
US, EU, JP
Approved
tezspire · tezepelumab · Tezspire · AMG 157 · MEDI9929 · tezepelumab-ekko
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG2 monoclonal antibody
Binds TSLP and prevents interaction with the TSLPR/IL-7Rα receptor complex
Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers.
구조화 데이터
Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers.
Non-inflammatory structural airway disease does not respond to cytokine blockade.
Human IgG2 monoclonal antibody
TSLP (thymic stromal lymphopoietin) · Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility.
Pharyngitis, arthralgia, and injection-site reactions; parasitic infection screening
The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
Severe asthma inadequately controlled on high-dose ICS plus another controller, regardless of phenotype
Add-on maintenance
Subcutaneous, self-administration pen available
210 mg q4w
Pharyngitis, arthralgia, and injection-site reactions; parasitic infection screening
The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra.
Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation.
Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility.
Non-inflammatory structural airway disease does not respond to cytokine blockade.
구조화 데이터
Human, cynomolgus
~26 days
Annualized exacerbation rate, pre-bronchodilator FEV1, FeNO, blood eosinophils
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (severe asthma add-on)
APPROVAL · 2021년 12월
Self-administration pen approved
APPROVAL · 2023년 2월
Chronic rhinosinusitis with nasal polyps indication
APPROVAL
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.